Jump to content

Hang Yin (scientist): Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
Line 34: Line 34:


==Awards==
==Awards==
* [[American Chemical Society]] David W. Robertson Award for Excellence in Medicinal Chemistry (2016)<ref>{{cite web|title=ACS C&EN|url=https://www.acsmedchem.org/?nd=robertsonaward}}</ref>
* [[American Chemical Society]] David W. Robertson Award for Excellence in Medicinal Chemistry (2016)<ref>{{cite web|title=ACS MEDI|url=https://www.acsmedchem.org/?nd=robertsonaward}}</ref>
* CAPA Distinguished Junior Faculty Award (2012)<ref>{{cite web|title=Chinese-American Chemistry Professor Association website|url=http://capa-chem.webs.com/capaawards.htm}}</ref>
* CAPA Distinguished Junior Faculty Award (2012)<ref>{{cite web|title=Chinese-American Chemistry Professor Association website|url=http://capa-chem.webs.com/capaawards.htm}}</ref>
* [[Stand Up to Cancer]] Innovative Research Grant Award (2010)<ref>{{cite web|title=SU2C news coverage|url=http://www.youtube.com/watch?v=GEenzig4QB4&feature=player_embedded}}</ref>
* [[Stand Up to Cancer]] Innovative Research Grant Award (2010)<ref>{{cite web|title=SU2C news coverage|url=http://www.youtube.com/watch?v=GEenzig4QB4&feature=player_embedded}}</ref>

Revision as of 01:07, 9 February 2016

Hang Hubert Yin
Born1976
Alma materYale University
Scientific career
FieldsChemistry, Biology
InstitutionsUniversity of Colorado Boulder
Doctoral advisorAndrew D. Hamilton

Hang Hubert Yin (born 5 July 1976) is a chemistry professor at the Department of Chemistry and Biochemistry[1] and the BioFrontiers Institute,[2] University of Colorado Boulder, a recipient of several young scientist awards for his research in chemical biology and drug discovery.

Career

Hang Hubert Yin was a pupil at the High School of Peking University. After studying for a bachelor's degree at the Peking University, he received his PhD from Yale University, New Haven in 2004 (supervisor: Professor Andrew D. Hamilton FRS) and then spent a post-doctoral period at the University of Pennsylvania School of Medicine under the supervision of Professor William DeGrado.[3] In 2007, he joined the faculty of the University of Colorado Boulder. His research interests lie at the interface of chemistry, biology, and engineering with particular focuses on structure-based drug design, cell signaling biochemistry, biotechnology development, and membrane protein simulations.[4]

Awards

Significant contributions

Yin's team showed that morphine causes inflammation by binding to the protein lymphocyte antigen 96, which, in turn, causes the protein to bind to an immune system receptor called Toll-like receptor 4 (TLR4).[13] The morphine-induced TLR4 activation attenuates pain suppression by opioid and enhances the development of opioid tolerance and addiction, drug abuse, and other negative side effects such as respiratory depression. The Yin group has developed drug candidates that can improve opioid-based pain management therapies.[14] On June 23, 2014, BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX) announced that it has in-licensed BL-1010, a novel compound for the treatment of neuropathic pain invented by Yin from the University of Colorado.[15] In 2015, Yin reported a new drug candidate that could change the way Parkinson's disease is treated.[16] The drug, called CU-CPT22, may help stop harmful inflammation in certain immune cells that is thought to cause Parkinson's.[17]

Notes

References

  1. ^ "University of Colorado Boulder Department of Chemistry and Biochemistry Webpage".
  2. ^ "University of Colorado BioFrontiers Institute Webpage".
  3. ^ "Yin AACR Bio".
  4. ^ "Yin Research Group Website".
  5. ^ "ACS MEDI".
  6. ^ "Chinese-American Chemistry Professor Association website".
  7. ^ "SU2C news coverage".
  8. ^ "University of Colorado Boulder news coverage".
  9. ^ "Elion Award lecture" (PDF).
  10. ^ "University of Colorado Technology Transfer Office news coverage".
  11. ^ "University of Colorado Boulder news coverage".
  12. ^ "Howard Hughes Medical Institute news coverage".
  13. ^ Making morphine work better, Nature 2012, 484: 419
  14. ^ Drahl, C. Small Molecules Target Toll-Like Receptors, C&EN 2012, 90: 33
  15. ^ "BioLineRx In-Licenses Novel Compound for Treatment of Neuropathic Pain" (Press release). MarketWatch.
  16. ^ Making Aggregation Less Aggravating, Science 2015, 348: 769
  17. ^ "CU Parkinson's research could revolutionize treatment".

Template:Persondata